Abstracts tagged "Outcome measures"

Abstract Number: 2402 • ACR Convergence 2024
Belimumab Reduces Disease Flares versus Placebo in Adults with Early Active Systemic Lupus Erythematosus: Results of a Large Integrated Analysis
Marta Mosca¹, Karen Costenbader², Joan Merrill³, Holly Quasny⁴, Christine Henning⁵, Steven Bloom⁶, Julia Harris⁶, Ciara O’Shea⁷, Tatsuya Atsumi⁸ and Ronald Van Vollenhoven⁹, ¹University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ²Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ³Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, ⁴GSK, Clinical Sciences, Durham, NC, ⁵GSK, Global Medical Affairs, Durham, NC, ⁶GSK, Immunology Biostatistics, Brentford, United Kingdom, ⁷GSK, Rheumatology, Global Medical Affairs, Dublin, Ireland, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ⁹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: SLE flares are associated with increased risk of organ damage/mortality; flare prevention is a key treatment goal.1 Initiating treatment earlier has benefits in autoimmune…
Abstract Number: L06 • ACR Convergence 2023
Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT)
Kathryn Torok¹, Paulina Horvei¹, Franziska Rosser¹, Kirsten Rose-felker², Vibha Sood², Adam Olsen², Nicole Hogue², Vickie Vandergrift², Lauren Farver², Devin Mcguire², Jonathan Li³, Haley Havrilla², Jessie Alexander⁴, Shawna McIntyre² and Paul Szabolcs¹, ¹University of Pittsburgh; UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Stanford Children's Hospital, Palo Alto, CA
Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is an inflammatory, fibrotic, and vasculopathic disease that causes severe multi-organ dysfunction leading to significant morbidity and early mortality.When patients…
Abstract Number: L19 • ACR Convergence 2023
A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks
George Spencer-Green¹, David Hunter², Thomas Schnitzer³, Sheue-Fang Shih⁴, Tien-Tzu Tai⁴, Cathy Kao⁴ and Siao-Ning Huang⁴, ¹Taiwan Liposome Company, Cambridge, MA, ²Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Taiwan Liposome Company, Taipei, Taiwan (Republic of China)
Background/Purpose: In osteoarthritis (OA) of the knee, intraarticular injections of corticosteroids can relieve pain, reduce inflammation, and improve mobility, but the effect is not predictable,…
Abstract Number: 0181 • ACR Convergence 2023
Increased Prevalence of and Acute Hospital Events Among Medicare Systemic Lupus Erythematosus Patients Living in Socially Vulnerable Counties in the United States
Emily Cosentino, John Pearce and Jim Oates, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is more prevalent and has greater adverse health outcomes in women, minorities, and individuals with low socioeconomic status (SES), particularly…
Abstract Number: 0523 • ACR Convergence 2023
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Fabian Proft¹, Désirée van der Heijde², Xenofon Baraliakos³, Joerg Ermann⁴, Carmen Fleurinck⁵, Ute Massow⁶, Natasha De Peyrecave⁷, Vanessa Taieb⁸, Astrid van Tubergen⁹ and Victoria Navarro-Compán¹⁰, ¹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵UCB Pharma, Oosterzele, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Colombes, France, ⁹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands, ¹⁰Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic rheumatic disease which requires optimal management and disease control. Patients (pts) can experience loss of response in the…
Abstract Number: 1055 • ACR Convergence 2023
Cancer Outcomes in Cancer Patients with Immune Checkpoint Inhibitor-induced Inflammatory Arthritis Treated with Glucocorticoids: Data from the CanRIO Retrospective Cohort
Vanissa Savarimuthu¹, Alexandra Ladouceur², Oliver Terry¹, Janet Roberts³, Janet Pope⁴, Thomas Appleton⁴, Sabrina Hoa⁵, Aurore Fifi-Mah⁶, Nancy Maltez⁷, Alexandra Saltman⁸, Megan Himmel⁸, Ines Colmegna⁹, Lindsay Cho¹⁰, Emma Schmidt¹⁰, Claudie Berger¹¹, Thomas Barnetche¹², Lourdes Gonzalez Arreola¹³, Carrie Ye¹⁴, Shahin Jamal¹⁵ and Marie Hudson¹⁶, ¹McGill University, Montreal, QC, Canada, ²Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ³Dalhousie University, Halifax, NS, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵University of Montreal, Brossard, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷The Ottawa Hospital, Ottawa, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹⁰University of British Columbia, Vancouver, BC, Canada, ¹¹RI-MUHC, Montreal, QC, Canada, ¹²Bordeaux University Hospital, Bordeaux, France, ¹³Arthritis Research Canada, Vancouver, BC, Canada, ¹⁴University of Alberta, Edmonton, AB, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada, ¹⁶McGill University, Montréal, QC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. A drawback of ICI therapy is their off-target effects known as immune-related adverse events…
Abstract Number: 1323 • ACR Convergence 2023
Distinct Treatment Responses in Patients with Rheumatoid Arthritis Receiving Filgotinib 200 Mg over 12 Months: A Post Hoc Analysis of FINCH 1
Peter C. Taylor¹, Yoshiya Tanaka², Emily Aiello³, Thomas P.A. Debray⁴, Chris Watson⁵, Kristina Harris⁶ and Gerd Burmester⁷, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Real-world Analytics, Cytel, Toronto, ON, Canada, ⁴Biostatistics, Galapagos NV, Mechelen, Belgium, ⁵Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, ⁶Medical Safety, Galapagos NV, Mechelen, Belgium, ⁷Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose: FINCH 1 (NCT02889796) was a Phase 3 randomized controlled trial evaluating filgotinib (FIL) in patients with rheumatoid arthritis and an inadequate response to methotrexate…
Abstract Number: 1623 • ACR Convergence 2023
Diffuse Juvenile Systemic Sclerosis Patients Show Distinct Organ Involvement, Antibody Pattern and Have More Severe Disease in the Largest jSSc Cohort of the World. Results from the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Kathryn Torok³, Ozgur Kasapcopur⁴, Amra Adrovic⁵, Brian Feldman⁶, FLAVIO SZTAJNBOK⁷, Maria Teresa TErreri⁸, Ana Sakamoto⁹, Sindhu Johnson¹⁰, Jordi Anton¹¹, Valda Stanevica¹², Raju Khubchandani¹³, Dieneke Schonenberg-Meinema¹⁴, Eslam Al-Abadi¹⁵, Ekaterina Alexeeva¹⁶, Maria Katsikas¹⁷, Sujata Sawhney¹⁸, Vanessa Smith¹⁹, Simone Appenzeller²⁰, Tadey Avcin²¹, Mikhail Kostik²², Thomas Lehman²³, Hana Malcova²⁴, Edoardo Marrani²⁵, Clare Pain²⁶, Natalia Vasquez-Canizares²⁷, Patricia Costa Reis²⁸, Mahesh Janarthanan²⁹, Maria Jose Santos³⁰, Sima Abu Alsaoud³¹, Christina Battagliotti³², Lillemor Berntson³³, blanca e r bica³⁴, Juergen Brunner³⁵, Daniela Kaiser³⁶, Dragana Lazarevic³⁷, Kirsten Minden³⁸, Farzana Nuruzzaman³⁹, Siri Opsahl Hetlevik⁴⁰, Yosef Uziel⁴¹ and Nicola Helmus⁴², ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁵Istanbul University - Cerrahpasa, Istanbul, Turkey, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷UFRJ/UERJ, São Paulo, Brazil, ⁸UNIFESP, São Paulo, Brazil, ⁹Federal University of São Paulo (UNIFESP), São Paulo, Brazil, ¹⁰Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ¹¹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹²Children's Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹³SRCC Childrens Hospital, Mumbai, India, ¹⁴Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁵Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom, ¹⁶Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ¹⁷Hospital de Pediatria Juan P Garrahan, Servicio de Inmunologia/Reumatologia, Buenos Aires, Argentina, ¹⁸Sir Ganga Ram Hospital, Uttar Pradesh, India, ¹⁹Ghent University Hospital, Gent, Belgium, ²⁰UNICAMP, Campinas, Brazil, ²¹University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ²²Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²³Hospital for Special Surgery, New York, NY, ²⁴Motol University Hospital, Prague, Czech Republic, ²⁵University of Florence, Firenze, Italy, ²⁶Alder Hey NHS Trust, Liverpool, United Kingdom, ²⁷Children’s Hospital at Montefiore, Bronx, NY, ²⁸Hospital de Santa Maria, Lisbon, Portugal, ²⁹SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, India, ³⁰Hospital Garcia de Orta, Almada, Lisboa, Portugal, ³¹Caritas baby Hospital, East Jerusalem, Israel, ³²Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ³³Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ³⁴Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ³⁵Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ³⁶Children's Hospital Lucerne, Lucerne, Switzerland, ³⁷Dept of Pediatric Rheumatology and Immunology Clinical Center Nis, Faculty of Medicine, University of Niš, Nis, Serbia, ³⁸Charité University Medicine and German Rheumatism Research Center Berlin, Berlin, Germany, ³⁹Stony Brook Children's Hospital, Stony Brook, NY, ⁴⁰Oslo University Hospital, Oslo, Norway, ⁴¹Pediatric Rheumatology Unit, Meir Medical Center, Kfar Saba, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel, ⁴²Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1,000,000 children. In adult patients there are significant differences between…
Abstract Number: 1980 • ACR Convergence 2023
Movement Evoked Pain as an Outcome Measure in Patients with Knee Osteoarthritis
Leila Bagherzadeh¹, Schnitzer Thomas², Santiago Espinosa-Salas¹ and Joana Barroso³, ¹Northwestern Physical Medicine and Rehabilitation Department, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Anesthesiology; Feinberg School of Medicine, Chicago, IL
Background/Purpose: Pain, being one of the most crucial symptoms associated with knee OA, serves as a significant outcome measure for the increasing number of studies…
Abstract Number: 2282 • ACR Convergence 2023
Increased Risk of Systemic Lupus Erythematosus Flare After COVID-19
Arthur Mageau¹, Christel Gerardin², Kankoe Sallah², Jean-Francois Timsit¹, Thomas Papo¹ and Karim Sacre¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hopitaux de Paris, Paris, France
Background/Purpose: The SARS-CoV2 pandemic reopened the unresolved question of whether and how a viral infection can trigger flares of immune-mediated inflammatory diseases such as systemic…
Abstract Number: 2538 • ACR Convergence 2023
Safety and Efficacy of Sodium-glucose Co-transporter 2 Inhibitors in Patients with Psoriasis and Concomitant Type 2 Diabetes Mellitus: A Population-based Cohort Study
Pin-Chia Huang¹, Debby Cheng², Megan H Noe³, Jui-En Lo⁴, Steven T Chen³ and Kevin Sheng-Kai Ma⁵, ¹Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, ²Harvard Medical School, Boston, MA, ³Department of Dermatology, Massachusetts General Hospital, Boston, MA, ⁴Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Psoriasis and type 2 diabetes mellitus (T2D) may share common underlying pathophysiology, in which the pathogenesis of psoriasis is mediated by NOD-like receptor family…
Abstract Number: 0246 • ACR Convergence 2023
Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Studies
Herbert Baraf¹, Alan Kivitz², Sheri Rhodes³, Sheldon Leung⁴, Olu Folarin⁴, Tania Gonzalez-Rivera⁵, Joanna Sobierska⁵, Jacquie Christie⁵, Anand Patel⁶, Wesley DeHaan⁴, Rehan Azeem⁴ and Peter Traber⁷, ¹The Center for Rheumatology and Bone Research, George Washington University, Rheumatology, Bethesda, MD, ²Altoona Center for Clinical Research, Duncansville, PA, ³Selecta Biosciences, Atlanta, GA, ⁴Selecta Biosciences, Inc., Watertown, MA, ⁵Swedish Orphan Biovitrum (Sobi), Stockholm, Sweden, ⁶Pioneer Research Solutions, Houston, TX, ⁷Selecta Biosciences, Gladwyne, PA
Background/Purpose: In patients with refractory gout, the inability to maintain serum uric acid (sUA) levels < 6 mg/dL leads to severe clinical manifestations for which…
Abstract Number: 0590 • ACR Convergence 2023
Comparing Safety and Efficacy of Sodium-Glucose Co-Transporter 2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes Mellitus
Jui-En Lo¹, Pin-Chia Huang², George Tsokos³, Vasileios Kyttaris⁴, Karen Costenbader⁵ and Kevin Sheng-Kai Ma², ¹Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ²Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴BIDMC, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i), originally approved as oral hypoglycemic agents for type 2 diabetes (T2D), have been shown to reduce progression to end-stage…
Abstract Number: 1065 • ACR Convergence 2023
Association Between COVID-19 and Disease-Modifying Antirheumatic Drugs
Ogheneyoma Akpoviroro¹, Nathan Sausers², Oghenetejiro Akpoviroro³, Queeneth Uwandu¹, Myriam Castagne⁴, Elga Rodrigues⁴, Lefulesele Khoalone¹, sara Humayun¹ and Jameson Woodard¹, ¹Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA, ²Pennsylvania State University, State College, PA, ³Mater Dei Hospital, Msida, Malta, ⁴Boston University, Boston, MA
Background/Purpose: Describe patients(pts) hospitalized with COVID-19C(C19) who were on disease modifying antirheumatic drugs (DMARDs) before admission(BA); assess if clinical outcomes differed from pts without BA…
Abstract Number: 1368 • ACR Convergence 2023
Development of the Sjögren’s-related Quality of Life (SRQoL) to Assess Health-related Quality of Life (HRQoL) in Sjögren’s
Benjamin A Fisher¹, Linda Stone², Jessica Marvel³, Pushpendra Goswami⁴, Monia Steenackers⁴, Gayle Kenney⁴, Chiara Perella⁵, Wolfgang Hueber⁴, Chloe Howse⁶, Elizabeth Gargon⁶, Aishwarya Chohan⁶, Megan Mayhew⁶ and Nicola Williamson⁶, ¹University of Birmingham, Birmingham, United Kingdom, ²The British Sjogren’s Syndrome Association, Birmingham, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharma AG, Riehen, Switzerland, ⁶Adelphi Values Patient-Centered Outcomes, Bollington, United Kingdom
Background/Purpose: Sjögren's is a heterogenous chronic auto-immune disease, characterized by excessive dryness of the eyes and mouth, as well as systemic complications which can significantly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].